StudyFinder
Search Results
1 Study Matches
Site for A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial with a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients with Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS): Assigned to PTM-001 (400mg) or placebo (no active ingredients) for 12 weeks after which all patients will receive the actual study medication, PTM-001 400mg daily for an additional 12 weeks. Males/Females 18 years of age and older. The goal of the study is assess the effect of PTM-001 on skin protein levels.
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT05020730
SITE00001113
Inclusion Criteria:
Had onset of symptoms consistent with HS at least 6 months; active HS for at least 2 monthsAgrees to follow all study directions
Exclusion Criteria:
Has other skin conditions that could interfere with viewing HSPositive for TB, HIV, Hepatitis B or Hepatitis C
Certain medications not allowed; study coordinator will discuss
For females: Pregnant, nursing or considering becoming pregnant
Skin Conditions